Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MVA HIV-B vaccine + vedolizumab
- Development stage
- Unknown
- Lead developer
- ANRS
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intravenous, Intramuscular, Subcutaneous
01
Overview
MVA HIV-B vaccine + vedolizumab is an investigational combination therapy being evaluated for the treatment of HIV-1 infection. The combination consists of the **MVA HIV-B therapeutic vaccine** (also known as MVATG17401) and the humanized monoclonal antibody **vedolizumab** (Entyvio). The MVA HIV-B vaccine utilizes a Modified Vaccinia Ankara (MVA) viral vector to deliver genetic sequences for the HIV-1 Clade B Gag, Pol, and Nef proteins, aiming to stimulate a robust HIV-specific T-cell immune response. Vedolizumab targets the **integrin α4β7** receptor, which is expressed on gut-homing CD4+ T-cells and serves as a potential co-receptor for HIV entry. By blocking α4β7, the therapy aims to protect CD4+ T-cells from infection and reduce viral replication, particularly in gut-associated lymphoid tissue (GALT). This synergistic approach is being tested in the Phase II EHVA T02/ANRS VRI07 trial to maintain viral suppression during analytical treatment interruption (ATI) in patients with HIV-1.
- Brand names
- Entyvio
- Other names
- MVA HIV-B + vedolizumabtherapeutic HIV MVA vaccine + vedolizumab
02
Targets
Gag (HIV-1 Gag polyprotein)HIV-1 Pol polyproteinα4β7 (Integrin alpha-4 beta-7 heterodimer)Nef (HIV-1 Nef)
Beyond the preview
Go deeper on MVA HIV-B vaccine + vedolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MVA HIV-B vaccine + vedolizumab.